Dr. Schiller on JAK Inhibitors in Myelofibrosis
By Gary J. Schiller, MD
Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.
Gary J. Schiller, MD, professor-in-residence, Department of Medicine, Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.
The most common mutation in myelofibrosis is found in JAK2, and most therapeutic options are directed against the JAK-STAT pathway, Schiller says. However, JAK2 mutations are not observed in all cases of myelofibrosis and there is uncertainty on the clonal advantage that is provided during hematopoiesis, Schiller explains.
There may be a therapeutic benefit to targeting JAK1 along with JAK2, but doing so can contribute to the adverse event profile, Schiller continues. Despite potential limitations, emerging therapies such as momelotinib and pacritinib (Vonjo) aim to target the JAK-STAT pathway, Schiller concludes.
Phase 1/2 Trial Pauses Enrollment for Evaluation of MGTA-117 in AML/MDS After Patient Death
FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis
Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
March 3rd 2022
Imetelstat Provides Durable Transfusion Independence in Lower-Risk MDS
Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer